Financial Performance - The company achieved operating revenue of ¥552,577,290.50, representing a year-on-year increase of 2.87%[3] - The total profit amounted to ¥159,045,522.15, reflecting an 8.04% increase compared to the previous year[3] - Net profit attributable to shareholders reached ¥131,575,798.33, up by 6.32% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥127,969,849.80, marking a 9.64% increase[3] - Basic earnings per share were ¥0.3082, which is a 6.32% increase from the previous year[3] Assets and Equity - Total assets at the end of the reporting period were ¥1,443,815,065.38, showing a growth of 6.62%[3] - Shareholders' equity attributable to the company was ¥1,265,354,551.40, an increase of 6.21%[3] Market and Operational Strategy - The company maintained stable revenue and profit growth despite slight price declines in some domestic products due to competition and policy factors[5] - The increase in revenue and profit was significantly supported by the growth in overseas sales of new and existing raw materials[5] - The company focused on optimizing management and reducing costs to enhance product competitiveness, ensuring stable revenue and gross profit growth[5]
森萱医药(920946) - 2025 Q4 - 年度业绩